This menu provides the list of EV mRNAs identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Maximum false positive rate (FPR): Maximum true positive rate (TPR):
  - FPR is the probability that an absent mRNA accidently have higher intensity than that mRNA.
  - TPR is the percentile of mRNA among the present mRNAs.
    Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Since there are multiple primers in the microarray, the same mRNA can have several FPR and TPR values.

mRNA name UniProt accession FPR TPR Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)P04264 1.4e-7 4.2e-1Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
Nat Cell Biol. 2008 Dec;10(12):1470-6. doi: 10.1038/ncb1800. Epub 2008 Nov 16.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin-6B) (K6B) (Type-II keratin Kb10)P04259 0.0e+0 1.7e-4Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin-6B) (K6B) (Type-II keratin Kb10)P04259 0.0e+0 2.1e-3Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin-6B) (K6B) (Type-II keratin Kb10)P04259 0.0e+0 3.3e-13Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 7 (Cytokeratin-7) (CK-7) (Keratin-7) (K7) (Sarcolectin) (Type-II keratin Kb7)P08729 0.0e+0 4.7e-4Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 1.4e-1Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells.
BMC Genomics. 2009 Nov 25;10:556. doi: 10.1186/1471-2164-10-556.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Cytokeratin-6D) (CK-6D) (Keratin-6A) (K6A) (Type-II keratin Kb6) (allergen Hom s 5)P02538 0.0e+0 3.1e-2Nanostructural and transcriptomic analyses of human saliva derived exosomes.
PLoS One. 2010 Jan 5;5(1):e8577. doi: 10.1371/journal.pone.0008577.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6B (Cytokeratin-6B) (CK-6B) (Keratin-6B) (K6B) (Type-II keratin Kb10)P04259 0.0e+0 7.2e-2Nanostructural and transcriptomic analyses of human saliva derived exosomes.
PLoS One. 2010 Jan 5;5(1):e8577. doi: 10.1371/journal.pone.0008577.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 2.7e-1Nanostructural and transcriptomic analyses of human saliva derived exosomes.
PLoS One. 2010 Jan 5;5(1):e8577. doi: 10.1371/journal.pone.0008577.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 2.9e-1RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.
BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 2.5e-1RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.
BMC Cancer. 2012 Jan 17;12:22. doi: 10.1186/1471-2407-12-22.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)P04264 4.8e-2 9.0e-2miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q9NSB2 2.2e-2 1.7e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)P04264 2.4e-2 1.9e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 5 (58 kDa cytokeratin) (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (Type-II keratin Kb5)P13647 2.7e-2 2.2e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668 1.9e-2 1.5e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q9NSB2 3.5e-2 1.5e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 1 (67 kDa cytokeratin) (Cytokeratin-1) (CK-1) (Hair alpha protein) (Keratin-1) (K1) (Type-II keratin Kb1)P04264 3.0e-2 1.2e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 5 (58 kDa cytokeratin) (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (Type-II keratin Kb5)P13647 3.5e-2 1.5e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668 2.8e-2 1.1e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668 0.0e+0 2.8e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 4.4e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q9NSB2 0.0e+0 4.6e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668 0.0e+0 2.8e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668 0.0e+0 3.9e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 2.6e-14 5.0e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 8.1e-5 4.8e-1Characterization of mRNA and microRNA in human mast cell-derived exosomes and their transfer to other mast cells and blood CD34 progenitor cells.
J Extracell Vesicles. 2012 Apr 16;1. doi: 10.3402/jev.v1i0.18389. eCollection 2012.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (65 kDa type II keratin) (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q99M73 0.0e+0 3.6e-1Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 75 (Cytokeratin-75) (CK-75) (Keratin-6 hair follicle) (mK6hf) (Keratin-75) (K75) (Type II keratin-K6hf) (Type-II keratin Kb18)Q8BGZ7 0.0e+0 1.7e-2Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (65 kDa type II keratin) (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q99M73 0.0e+0 8.5e-2Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 75 (Cytokeratin-75) (CK-75) (Keratin-6 hair follicle) (mK6hf) (Keratin-75) (K75) (Type II keratin-K6hf) (Type-II keratin Kb18)Q8BGZ7 0.0e+0 4.5e-2Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cuticular Hb4 (65 kDa type II keratin) (Keratin-84) (K84) (Type II hair keratin Hb4) (Type-II keratin Kb24)Q99M73 0.0e+0 5.5e-3Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 75 (Cytokeratin-75) (CK-75) (Keratin-6 hair follicle) (mK6hf) (Keratin-75) (K75) (Type II keratin-K6hf) (Type-II keratin Kb18)Q8BGZ7 0.0e+0 5.3e-3Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes.
J Extracell Vesicles. 2013 May 17;2. doi: 10.3402/jev.v2i0.20167. eCollection 2013.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 5 (58 kDa cytokeratin) (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (Type-II keratin Kb5)P13647 0.0e+0 5.4e-5Two distinct extracellular RNA signatures released by a single cell type identified by microarray and next-generation sequencing.
RNA Biol. 2016 Oct 28:0.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 5 (58 kDa cytokeratin) (Cytokeratin-5) (CK-5) (Keratin-5) (K5) (Type-II keratin Kb5)P13647 0.0e+0 1.9e-1Two distinct extracellular RNA signatures released by a single cell type identified by microarray and next-generation sequencing.
RNA Biol. 2016 Oct 28:0.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 7 (Cytokeratin-7) (CK-7) (Keratin-7) (K7) (Sarcolectin) (Type-II keratin Kb7)P08729 0.0e+0 2.2e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 8.2e-2The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Cytokeratin-6D) (CK-6D) (Keratin-6A) (K6A) (Type-II keratin Kb6) (allergen Hom s 5)P02538 0.0e+0 4.7e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 7 (Cytokeratin-7) (CK-7) (Keratin-7) (K7) (Sarcolectin) (Type-II keratin Kb7)P08729 0.0e+0 3.1e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		ENOG410YY6B20 / 0 / 20
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) (Type-II keratin Kb8)P05787 0.0e+0 1.3e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		ENOG410YY6B20 / 0 / 20
[1]